Delving into the Latest Updates on Sygnis Bioscience GmbH & Co KG with Synapse

概览

关联

4

项与 Sygnis Bioscience GmbH & Co KG 相关的药物

AX-208

靶点-

作用机制-

在研机构-

原研机构

Sygnis Bioscience GmbH & Co KG

在研适应症-

非在研适应症

帕金森病

最高研发阶段终止

首次获批国家/地区-

首次获批日期-

AX-205

靶点-

作用机制-

在研机构-

原研机构

Sygnis Bioscience GmbH & Co KG

在研适应症-

非在研适应症

运动神经元疾病

最高研发阶段终止

首次获批国家/地区-

首次获批日期-

HP-228

靶点-

作用机制-

在研机构-

原研机构

Sygnis Bioscience GmbH & Co KG

在研适应症-

非在研适应症

哮喘 [+5]

最高研发阶段终止

首次获批国家/地区-

首次获批日期-

2

项与 Sygnis Bioscience GmbH & Co KG 相关的临床试验

EUCTR2008-006444-19-SK / Not yet recruiting临床2期

AXIS 2: AX200 for the treatment of ischemic strokeA multinational, multicenter, randomized, doubleblind,placebo-controlled, phase II trial

开始日期2009-08-13

申办/合作机构

Sygnis Bioscience GmbH & Co KG

NCT00927836 / Completed临床2期

AXIS 2: AX200 for the Treatment of Ischemic Stroke - A Multinational, Multicenter, Randomized, Doubleblind, Placebo-controlled Phase II Trial

The purpose of this study is to assess the efficacy of AX200 (filgrastim) in the treatment of acute ischemic stroke and to assess the safety and tolerability of AX200.

开始日期2009-05-01

申办/合作机构

Sygnis Bioscience GmbH & Co KG

100 项与 Sygnis Bioscience GmbH & Co KG 相关的临床结果

登录后查看更多信息

0 项与 Sygnis Bioscience GmbH & Co KG 相关的专利（医药）

登录后查看更多信息

2

项与 Sygnis Bioscience GmbH & Co KG 相关的文献（医药）

2008-06-01·Current Medicinal Chemistry2区 · 医学

Old Friends in New Constellations - the Hematopoetic Growth Factors G-CSF, GMCSF, and EPO for the Treatment of Neurological Diseases

2区 · 医学

Review

作者: Maurer, M. H. ; Schneider, A. ; Schaebitz, W.-R.

Currently, growth factors which have been identified in hematopoiesis and angiogenesis are re-considered as therapeutical agents in a number of neurological diseases, mainly neurodegenerative disorders like Parkinson's Disease, amyotrophic lateral sclerosis (ALS), or cerebrovascular events such as stroke. Among these growth factors, erythropoietin (EPO) and granulocyte colony-stimulating growth factor (G-CSF) are the most prominent. With regard to neurological disease, EPO has been tested in clinical trials for potential use in stroke, schizophrenia, and addiction, G-CSF is currently under clinical investigation for stroke treatment. The major advantage of these growth factors is their well-described pharmacological behavior and their clinical use over several years. A number of mechanisms of action in the CNS have been identified that are probably important for the beneficial action of these factors in animal models of disease, the most relevant relating to neuroprotection, neuroplasticity and stem cell growth and differentiation. In this review, we will discuss the current efforts and prerequisites of novel growth factor therapies for neurodegenerative diseases with regard to their possible mechanism of action on the molecular level and their effects on brain-derived stem cell populations. Additionally, we will describe the necessities for future research before such therapies can be envisioned.

BMC Genomics

The functional genome of CA1 and CA3 neurons under native conditions and in response to ischemia

作者: Kuschinsky, Wolfgang ; Pahlavan, Payam S. ; Sorgenfrei, Oliver ; Boehm, Christine ; Bach, Alfred ; Rossner, Moritz ; Wafzig, Oliver ; Maurer, Martin ; Schroeck, Helmut ; Krueger, Carola ; Vogt, Gerhard ; Newrzella, Dieter ; Hiemisch, Holger ; Eisenhardt, Gisela ; Schramm, Nadine ; Schneider, Armin

Background The different physiol. repertoire of CA3 and CA1 neurons in the hippocampus, as well as their differing behavior after noxious stimuli are ultimately based upon differences in the expressed genome.We have compared CA3 and CA1 gene expression in the uninjured brain, and after cerebral ischemia using laser microdissection (LMD), RNA amplification, and array hybridization.Results Profiling in CA1 vs. CA3 under normoxic conditions detected more than 1000 differentially expressed genes that belong to different, physiol. relevant gene ontol. groups in both cell types.The comparison of each region under normoxic and ischemic conditions revealed more than 5000 ischemia-regulated genes for each individual cell type.Surprisingly, there was a high co-regulation in both regions.In the ischemic state, only about 100 genes were found to be differentially expressed in CA3 and CA1.The majority of these genes were also different in the native state.A minority of interesting genes (e.g. inhibin beta A) displayed divergent expression preference under native and ischemic conditions with partially opposing directions of regulation in both cell types.Conclusions The differences found in two morphol. very similar cell types situated next to each other in the CNS are large providing a rational basis for physiol. differences.Unexpectedly, the genomic response to ischemia is highly similar in these two neuron types, leading to a substantial attenuation of functional genomic differences in these two cell types.Also, the majority of changes that exist in the ischemic state are not generated de novo by the ischemic stimulus, but are preexistant from the genomic repertoire in the native situation.This unexpected influence of a strong noxious stimulus on cell-specific gene expression differences can be explained by the activation of a cell-type independent conserved gene-expression program.Our data generate both novel insights into the relation of the quiescent and stimulus-induced transcriptome in different cells, and provide a large dataset to the research community, both for mapping purposes, as well as for physiol. and pathophysiol. research.

100 项与 Sygnis Bioscience GmbH & Co KG 相关的药物交易

登录后查看更多信息

100 项与 Sygnis Bioscience GmbH & Co KG 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年11月05日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

其他

4

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

HP-228	肥胖更多	终止
AX-205	运动神经元疾病更多	终止
AX-208	帕金森病更多	终止
Filgrastim(Axaron Bioscience) ( CSF-3R )	急性缺血性卒中更多	无进展